News
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
3don MSN
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
3don MSN
Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
The company now expects full-year sales growth of 8% to 14%, down significantly from 13% to 21%. Its guidance for operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback